511 related articles for article (PubMed ID: 11912556)
1. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
[TBL] [Abstract][Full Text] [Related]
2. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
3. Blood coagulation and fibrinolysis in obese NIDDM patients.
Avellone G; Di Garbo V; Cordova R; Rotolo G; Abruzzese G; Raneli G; De Simone R; Bompiani GD
Diabetes Res; 1994; 25(2):85-92. PubMed ID: 7648783
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
5. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
6. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.
McGill JB; Schneider DJ; Arfken CL; Lucore CL; Sobel BE
Diabetes; 1994 Jan; 43(1):104-9. PubMed ID: 8262307
[TBL] [Abstract][Full Text] [Related]
7. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
DeSouza CA; Jones PP; Seals DR
Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
[TBL] [Abstract][Full Text] [Related]
8. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
McBane RD; Hardison RM; Sobel BE;
Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
[TBL] [Abstract][Full Text] [Related]
9. Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.
Avellone G; di Garbo V; Cordova R; Rotolo G; Raneli G; de Simone R; Bompiani G
Metabolism; 1997 Aug; 46(8):930-4. PubMed ID: 9258277
[TBL] [Abstract][Full Text] [Related]
10. [Evolution of fibrinolysis status with D-dimer level and the rate of plasminogen activator inhibitor type-1/D-dimer in acute coronary syndrome patients complicated with impaired glucose tolerance].
Wu WD; Xu YH; Tan PY
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Aug; 15(8):472-5. PubMed ID: 12919647
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
[TBL] [Abstract][Full Text] [Related]
12. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.
Erem C; Hacihasanoğlu A; Celik S; Ovali E; Ersöz HO; Ukinç K; Deger O; Telatar M
Med Princ Pract; 2005; 14(1):22-30. PubMed ID: 15608477
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
14. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
15. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women.
Peverill RE; Teede HJ; Malan E; Kotsopoulos D; Smolich JJ; McGrath BP
Clin Sci (Lond); 2007 Nov; 113(9):383-91. PubMed ID: 17608627
[TBL] [Abstract][Full Text] [Related]
16. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.
Belalcazar LM; Ballantyne CM; Lang W; Haffner SM; Rushing J; Schwenke DC; Pi-Sunyer FX; Tracy RP;
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1689-95. PubMed ID: 21512162
[TBL] [Abstract][Full Text] [Related]
17. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
19. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.
Semeraro F; Giordano P; Faienza MF; Cavallo L; Semeraro N; Colucci M
Thromb Haemost; 2012 Aug; 108(2):311-7. PubMed ID: 22740053
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
